Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran Therapeutics ("Taran") a privately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback